U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
NCT ID: NCT03886571
Last Updated: 2023-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2018-09-15
2024-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection
NCT00584363
Biospecimens for Identification of Diseases of the Pancreas.
NCT01392027
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
NCT00900094
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
NCT03214991
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer
NCT02079363
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This protocol supports this effort by providing investigators with access to a wide variety of pancreatic tissues and biospecimens for translational studies in pancreatic cancer. This protocol covers the collection of clinical data and biospecimens (blood; malignant, benign, or precancerous pancreatic tumor; and adjacent normal tissues) from patients with, or suspected to have, pancreatic cancer. Additionally, saliva and cyst fluid, may be collected in the future from patients with pancreatic cysts. These will be shared with the Pancreatic Cancer Detection Consortium for further analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals undergoing or have previously undergone a diagnostic procedure (i.e. EUS or ERCP) evaluation or surgery.
* Willingness and ability to donate biospecimens for the purpose of research.
* Subjects must have had diagnostic procedure or surgery after September 1, 2017.
Exclusion Criteria
* Inability to donate biospecimens.
* Females pregnant or lactating.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor Research Institute
OTHER
Hoag Memorial Hospital Presbyterian
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Demeure, MD
Program Director for Precision Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
119-17-CA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.